No Data
No Data
No Data
No Data
No Data
Two-wheel drive: IGG (0799.HK) achieves strategic breakthroughs with long-term vision and diversified layout
A conversation with IGG Executive Director and Chief Operating Officer Xu Yuan
Gelonghui FinanceApr 11 01:32 ET
IGG (00799.HK) grants a total of 965,600 bonus shares
Gelonghui, April 10, 丨 IGG (00799.HK) announced that on April 10, 2024, based on the recommendation of the company's remuneration committee, the board of directors decided to grant a total of 965,600 award shares to (i) a share award grantor (i.e. Mr. Zheng Deyang) who is a group related person and employee, and (ii) 34 other share award grantees who are group employees, using internal resources provided by the company to the trustee, to be purchased on the public market by the trustee Giving people Accepted.
Gelonghui FinanceApr 10 09:10 ET
The March ranking of Chinese mobile game revenue and downloads in overseas markets has been released! “Last War: Survival Game” hits the revenue list for the first time
The Zhitong Finance App learned that according to the latest data from the Sensor Tower store intelligence platform, in March 2024, the revenue and download rankings of Chinese mobile game products in overseas markets were released. The 4X strategy mobile game “Last War: Survival Game”, which combines casual gameplay, increased by 40% in March, breaking through 100 million US dollars, a record high, and topped the overseas mobile game revenue list for the first time.
Zhitong FinanceApr 9 22:49 ET
BOC International: Maintaining China Biopharmaceutical's “Buy” Rating Target Price of HK$4.8
BOC International released a research report stating that it maintains the “buy” rating of China Biopharmaceuticals (01177), with a target price of HK$4.8, and is optimistic that the 2024 performance recovery and the value of the innovation pipeline will continue to be realized. The company recently established a strategic partnership with Boehringer Ingelheim (BI). The bank believes that this cooperation will further consolidate the company's multi-target layout in the field of solid tumors, have strong collaboration with existing products, and increase the company's revenue and profits. BOB International's main views are as follows: Cooperation in the field of major oncology is highly collaborative with existing pipelines: the company recently established a strategic partnership with Boehringer Ingelheim (BI), and together
新浪港股Apr 9 22:13 ET
Jefferies Adjusts IGG's Price Target to HK$3.84 From HK$4.84, Keeps at Buy
05:28 AM EDT, 03/29/2024 (MT Newswires) -- Jefferies Adjusts IGG's Price Target to HK$3.84 From HK$4.84, Keeps at Buy Price (HKD): $3.30, Change: $-0.27, Percent Change: -7.56%
MT NewswiresMar 29 05:28 ET
Are IGG Inc's (HKG:799) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
IGG (HKG:799) has had a rough month with its share price down 14%. It seems that the market might have completely ignored the positive aspects of the company's fundamentals and decided to weigh-in m
Simply Wall StMar 28 19:21 ET
Pikachu Heng : crushing today and more to come
No Data
No Data